Skip to main content
. 2018 Sep 11;9(71):33482–33499. doi: 10.18632/oncotarget.26060

Figure 8. Effects of the HDAC inhibitor vorinostat and its combination with JQ1, FX1, or volasertib on cell growth, cell cycle, and apoptosis in DH-My6 cells.

Figure 8

(A) Cell growth assay following treatment with the indicated doses of vorinostat. (B) Cell cycle analysis conducted at 48 h after treatment with vorinostat (1 μM). (C) Apoptosis assay conducted at 48 h after treatment with the indicated doses of vorinostat. (D) Cell growth assay following treatment with the various doses of vorinostat, JQ1, and their combinations for 72 h. (E) Apoptosis assay conducted at 48 h after a single treatment with vorinostat (500 nM), JQ1 (500 nM), and their combination at doses that did not induce significant apoptosis individually. (F) Cell growth assay following treatment with the various doses of vorinostat, FX1, and their combinations for 72 h. (G) Apoptosis assay conducted at 48 h after single treatment with vorinostat (500 nM), FX1 (25 μM), and their combination at doses that did not induce significant apoptosis individually. (H) Cell growth assay following treatment with the various doses of vorinostat, volasertib, and their combinations for 72 h. (I) Apoptosis assay conducted at 48 h after a single treatment with vorinostat (500 nM), volasertib (2.5 nM), and their combination at doses that did not induce significant apoptosis individually. Data are shown as the mean ± SEM of three independent experiments. Significant expression differences are shown as *P < 0.05; **P <0.01.